Prevalence, Clinical Characteristics, Progression, and Management of Neurofibromatosis Type 1 in Egypt (NF1-Egy)

Trial Identifier:	D134BR00005
Sponsor:	AstraZeneca
Start Date:	November 2025
Primary Completion Date:	September 2026
Study Completion Date:	September 2026

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
Egypt	Alexandria, Egypt
Egypt	Assiut, Egypt
Egypt	Aswan, Egypt
Egypt	Cairo, Egypt
Egypt	Mansoura, Egypt
Egypt	Sohag, Egypt
Egypt	Tanta, Egypt
Egypt	zagazig, Egypt

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.